Nurse Practitioner · San Diego, CA
NPI
1598872319
Since 2006
Specialty
Nurse Practitioner
Code 363L00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
3033 Bunker Hill St, 3rd Floor
San Diego, CA, 92109
Phone (858) 581-8086
Groups this clinician bills Medicare through
Medicare paid, 2024
$1,518
22 services
Medicare patients, 2024
15
Average age 62
Drug cost, 2024
$280K
1,095 prescriptions
Company payments, 2023
$188
From 2 companies
Medicare prescription drug claims, 2024
In 2024, the drug Omana T Kaliangara prescribed most often to Medicare patients was Insulin Glargine-Yfgn, with 155 prescriptions and refills. In total Omana T Kaliangara wrote 1,095 Medicare prescriptions that cost $280K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-02-28.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Insulin Glargine-Yfgn Generic | 155 | 424 | 59 | $19K |
| Humalog Kwikpen U-100 Insulin Lispro | 133 | 310 | 59 | $51K |
| Humulin N Insulin Nph Human Isophane | 123 | 348 | 52 | $17K |
| Humalog Insulin Lispro | 105 | 304 | 46 | $32K |
| Humulin R Insulin Regular, Human | 88 | 253 | 41 | $14K |
| Humulin N Kwikpen Insulin Nph Human Isophane | 69 | 162 | 28 | $12K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 43 | 110 | 22 | $1,417 |
| Ozempic Semaglutide | 41 | 44 | Under 11 | $32K |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 35 | 107 | 21 | $1,104 |
| Ultra-Fine Short Pen Needle Pen Needle, Diabetic | 31 | 85 | 19 | $1,407 |
| Glipizide Generic | 24 | 79 | 11 | $254 |
| Veo Insulin Syringe Syrge-Ndl,ins 0.3 Ml Half Mark | 20 | 54 | 12 | $661 |
| Veo Insulin Syringe Syringe And Needle,insulin,1ml | 19 | 58 | Under 11 | $743 |
| Atorvastatin Calcium Generic | 17 | 57 | Under 11 | $229 |
| Victoza 3-Pak Liraglutide | 17 | 19 | Under 11 | $15K |
Brand drugs: 812 claims; generic drugs: 110 claims.
Money and other things of value reported by the companies
In 2023, drug and medical device companies paid Omana T Kaliangara $188 ($188 in general payments such as food, travel and fees) from 2 companies. The largest payer was Dexcom, Inc. with $102.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.